Details of the Drug

General Information of Drug (ID: DMZJUV6)

Drug Name
CSJ117
Synonyms Ecleralimab
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Phase 2 [1]
Chronic obstructive pulmonary disease CA22 Phase 2 [2]
Drug Type
Antibody
Cross-matching ID
TTD ID
DU6O4B
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Thymic stromal lymphopoietin (TSLP) TTHMW3T TSLP_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 12 Disease of the respiratory system
Disease Class ICD-11: CA23 Asthma
The Studied Tissue Nasal and bronchial airway
The Studied Disease Asthma [ICD-11:CA23]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Thymic stromal lymphopoietin (TSLP) DTT TSLP 8.89E-01 0.3 0.26
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04410523) A 12-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Study to Assess the Efficacy and Safety of CSJ117, When Added to Existing Asthma Therapy in Patients >= 18 Years of Age With Severe Uncontrolled Asthma. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04882124) A 12-week Randomized, participant-and Investigator-blinded, Placebo-controlled, Parallel Group Study to Explore the Efficacy, Pharmacodynamics, Safety, and Pharmacokinetics of Two Doses of Inhaled CSJ117 in Adults With Chronic Obstructive Pulmonary Disease (COPD). U.S.National Institutes of Health.
3 TSLP Inhibitors for Asthma: Current Status and Future Prospects. Drugs. 2020 Apr;80(5):449-458.